Serena Nik-Zainal

Serena Nik-Zainal is a British-Malaysian clinician who is a consultant in clinical genetics and Cancer Research UK advanced clinician scientist at the University of Cambridge.[1][2] She makes use of genomics for clinical applications. She was awarded the Crick Lecture by the Royal Society in 2021. Serena Nik-Zainal was also recognized as one of the 100 Influential Women in Oncology by OncoDaily.[3]

Serena Nik-Zainal
Born
England
Alma materUniversity of Cambridge
AwardsCrick Lecture (2021)
Scientific career
FieldsGenomics
InstitutionsUniversity of Cambridge
Wellcome Sanger Institute
ThesisExploring mutational signatures in twenty-one breast cancers (2013)
Websitewww.sanger.ac.uk/person/nik-zainal-serena/

Early life and education

Nik-Zainal was born in England.[4] Her father was a cardiologist who was involved in the first coronary artery bypass surgery to take place in Malaysia.[5] She was supported by Petronas to attend the University of Cambridge, where she studied medicine.[4] She moved to the Wellcome Sanger Institute in 2009, where she started doctoral research[6] using whole genome sequencing to better understand breast cancer.[7] Whole genome sequencing allows for Nik-Zainal to understand the frequency, distribution and mutation patterns of cancer. She showed that it was possible to identify mutational signatures using downstream analysis, and that algorithms could be used to identify abnormalities quickly. These signatures are left by mutations that occur during the development of cancer. During her research she identified the hypermutation kataegis.[4][8]

Research and career

Nik-Zainal was awarded a Wellcome Trust Clinical Fellowship in 2013. She moved to the Wellcome Sanger Institute, where she explored whole genome sequencing of tumours. Her research combined computational processes and cell-based model systems.

In 2017 Nik-Zainal moved to the University of Cambridge, supported by a Cancer Research UK Advanced Clinician Scientist fellowship.[4] Her research group investigate the physiology of mutagenic activity.[9] She has studied both driver and passenger mutations. Passenger mutations can be used to understand how DNA is damaged and repaired during tumorigenesis. Nik-Zainal looks to identify mutational signatures in human cancers and the aetiologies that give rise to them. Nik-Zainal leads the clinical research project Insignia, which researches mutational signatures in people with neurodegeneration, ageing syndromes and DNA repair defects.[10] Nik-Zainal has continued to develop computational approaches to identify DNA damage in tumours, insight into which can help to determine the most effective treatment in cancer patients.[11][12]

As of 2022, she has an h-index of 63.[1]

Awards and honours

She was awarded the Crick Lecture by the Royal Society for her work on he aetiology of cancer and contributions to cancer therapies.[13] In 2021 she was awarded a Research Professorship at the National Institute for Health Research (NIHR).[14] She was the first woman to win the Josef Steiner Cancer Research Award in 2019.[15]

Selected publications

Her publications[1][2]

  • Signatures of mutational processes in human cancer[16]
  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences[17]
  • Massive genomic rearrangement acquired in a single catastrophic event during cancer development[18]

Personal life

Nik-Zainal has two children.[5]

References
  1. Serena Nik-Zainal publications indexed by Google Scholar
  2. Serena Nik-Zainal publications from Europe PubMed Central
  3. "100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023". OncoDaily.
  4. Anon (2018-10-02). "Biography". cam.ac.uk. Retrieved 2021-08-25.
  5. Jun, Soo Wern (18 October 2019). "Memories of 'bunga telang': Award-winning Dr Serena Nik-Zainal on how cardiologist dad inspired life in medicine | Malay Mail". malaymail.com. Retrieved 2021-08-25.
  6. Nik-Zainal, Serena (2013). Exploring mutational signatures in twenty-one breast cancers. cam.ac.uk (PhD thesis). University of Cambridge. OCLC 890148227. EThOS uk.bl.ethos.607929.
  7. "In view: Customised breast cancer care". healthcare-in-europe.com. Retrieved 2021-08-25.
  8. Serena Nik-Zainal; Judy E Garber; David C Wedge; et al. (25 May 2012). "Mutational processes molding the genomes of 21 breast cancers". Cell. 149 (5): 979–93. doi:10.1016/J.CELL.2012.04.024. ISSN 0092-8674. PMC 3414841. PMID 22608084. Wikidata Q24620915.
  9. Anon (2018-10-02). "Serena Nik-Zainal". www.mrc-cu.cam.ac.uk. Retrieved 2021-08-25.
  10. "Dr Serena Nik-Zainal". Academic Department of Medical Genetics. Retrieved 2021-08-25.
  11. "New cancer algorithm flags genetic weaknesses in tumours". EurekAlert!. Retrieved 2021-08-25.
  12. "Cambridge Spotlight: New approaches to fighting cancer". Varsity Online. Retrieved 2021-08-25.
  13. "Francis Crick Medal and Lecture | Royal Society". royalsociety.org. Retrieved 2021-08-25.
  14. "Serena Nik-Zainal awarded an NIHR Research Professorship". Cambridge Centre Early Detection. 2022-01-06. Retrieved 2022-01-06.
  15. "Award Ceremony of the Dr. Josef Steiner Cancer Research prize". Academic Department of Medical Genetics. 2019-10-16. Retrieved 2021-08-25.
  16. Alexandrov LB; Nik-Zainal S; Wedge DC; et al. (22 August 2013). "Signatures of mutational processes in human cancer". Nature. 500 (7463): 415–21. doi:10.1038/NATURE12477. ISSN 1476-4687. PMC 3776390. PMID 23945592. Wikidata Q29547191. (erratum)
  17. Serena Nik-Zainal; Helen Davies; Johan Staaf; et al. (2 May 2016). "Landscape of somatic mutations in 560 breast cancer whole-genome sequences". Nature. 534 (7605): 47–54. doi:10.1038/NATURE17676. ISSN 1476-4687. PMC 4910866. PMID 27135926. Wikidata Q34046731.
  18. Philip J Stephens; Chris D Greenman; Beiyuan Fu; et al. (7 January 2011). "Massive genomic rearrangement acquired in a single catastrophic event during cancer development". Cell. 144 (1): 27–40. doi:10.1016/J.CELL.2010.11.055. ISSN 0092-8674. PMC 3065307. PMID 21215367. Wikidata Q24631164.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.